Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 16th Preview)
-
European GLP-1 expansion
The European Medicines Agency’s human medicines committee (CHMP) endorsed Eli Lilly’s oral GLP-1 therapy orforglipron, clearing a regulatory milestone as the company tries to close the gap with Novo Nordisk’s oral GLP-1 franchise. The CHMP recommendation adds momentum to Lilly’s push to broaden the addressable market for GLP-1 drugs beyond injectables. The decision comes at a time when oral GLP-1 competition is intensifying and dosing convenience is becoming a differentiator in cardiometabolic care. Payers and clinicians will be watching for label details that could shape sequencing and combination strategies in real-world practice. For Lilly, the CHMP step is the latest in a broader portfolio strategy that increasingly targets metabolic-disease populations earlier and more broadly.
-
AI-enabled target discovery dealmaking
AstraZeneca signed a $1.5 billion licensing and drug discovery collaboration with insitro to apply AI-driven target discovery to metabolic dysfunction–associated steatohepatitis (MASH) and cardiomyopathies. AstraZeneca will pay an upfront amount and could make additional development and commercial milestones tied to selected programs. The collaboration centers on insitro’s Virtual Human platform, which integrates large-scale human and cellular data with AI target identification and drug design. AstraZeneca will nominate targets into discovery through development candidate selection, then use its clinical and regulatory capabilities to advance the programs. The deal underscores a growing shift toward outsourcing early, target-selection work to AI platforms—especially in complex cardiometabolic biology where causal biology and patient stratification remain high barriers.
-
RNAi public-market push
City Therapeutics priced a $200 million initial public offering to fund RNA interference programs aimed at moving beyond liver delivery. The company’s lead RNAi therapy portfolio and tissue-delivery platform are designed to support knockdown in extrahepatic targets, a key challenge for in vivo RNAi. City Therapeutics has highlighted prior partnerships spanning Bausch + Lomb in eye diseases and Biogen in central nervous system disorders, signaling industrial validation of its delivery approach. The IPO also positions City as part of a broader 2026 resurgence in biotech listings. The capital raise is likely to accelerate clinical testing and manufacturing scale-up as RNAi developers compete to prove durability, safety, and meaningful pharmacology outside the liver.
-
Therapeutic plasma exchange safety in pediatrics
A five-year retrospective single-center analysis of 144 critically ill children found therapeutic plasma exchange showed a generally strong safety profile. Researchers reported that multiple organ dysfunction syndrome and vasopressor use were independently associated with mortality, reinforcing that disease severity—not the procedure itself—drove the worst outcomes. The work provides additional real-world evidence for clinicians using TPE in pediatric critical care, a setting where adverse event risk and uncertainty can complicate decisions. While retrospective by design, the findings support continued use in carefully selected cases and provide a reference risk profile as prospective studies build evidence for pediatric TPE indications.
-
CAR-T clinical signal in myeloma
A phase 1 trial reported all 38 evaluable participants with relapsed or refractory multiple myeloma responded to the investigational BCMA-targeted CAR-T therapy anito-cel, with a favorable safety profile. The results highlight durable long-term benefit signals across a relapsed population. The dataset adds to the growing evidence that BCMA CAR-T can achieve deep response rates, but it also raises the bar for next-line comparisons against existing CAR-T and bispecific antibody regimens. For developers, the trial’s emphasis on consistent responses supports continued focus on manufacturing reliability, immune persistence, and toxicity management as differentiation points in commercial CAR-T.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.